Patricio Massera, AGC Biologics CEO

AGC un­veils Ger­man ex­pan­sion plans as gene and cell ther­a­py man­u­fac­tur­ing com­pe­ti­tion heats up

AGC Bi­o­log­ics is sig­nif­i­cant­ly ex­pand­ing a Ger­man site fo­cus­ing on cell and gene ther­a­pies.

The Seat­tle com­pa­ny will add an­oth­er cGMP man­u­fac­tur­ing line at its Hei­del­berg fa­cil­i­ties, which al­ready fea­ture 100-liter and 1,000-liter man­u­fac­tur­ing ca­pac­i­ties for mi­cro­bial pro­tein and cell and gene ther­a­py. The site will add more ware­house ca­pac­i­ty too, which AGC says will help the com­pa­ny pre­pare for the rapid in­crease in de­mand.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.